ANALYSIS OF HIGH DOSE AND LONG-TERM PREDNISONE THERAPY ON OSTEOCALCIN LEVELS IN CHILDREN WITH NEPHROTIC SYNDROME (STUDY AT PEDIATRIC DEPARTMENT NEPHROLOGY DIVISION OF DR. SOETOMO TEACHING HOSPITAL SURABAYA)
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i6.17124Keywords:
Osteocalcin, Nephrotic syndrome, Prednisone, Corticosteroid, High dose prednisone, Long-term prednisone, Bone formation, Bone marker, PediatricAbstract
Objective: The objective of the study to analyze osteocalcin levels in induction and alternate phase, associated with clinical manifestation.
Methods: We conducted a prospective longitudinal study. This study was subject to approval by the Ethics Committee of Dr. Soetomo Teaching Hospital Surabaya. Osteocalcin levels were measured before and after induction phases and 4 weeks after the alternate phase. Samples were collected in the morning at 08.00-09.00 am.
Results: A total of 15 patients were included in this study. The suppression of osteocalcin levels in the induction phase was 53.33%. After the alternate phase, osteocalcin levels increased 175.82%. Clinical manifestation as bone pain/cramps only appeared 33% in the induction phase and 20% in the alternate phase. The mean suppression of osteocalcin levels in the group with induction phase duration therapy ≥28 days and without calcium supplementation was higher than 21-27 days and with calcium supplementation. Osteocalcin levels increased in the alternate phase also in patients with and without calcium supplementation. The result of analysis showed there was no significant difference among all groups (p>0.05).
Conclusion: Suppression of osteocalcin levels was reversible after the alternate phase. It shows that tapering off regimen is important. Clinical sign as pain bone/cramps almost showed no manifest in all of these patients.
Â
Downloads
References
KDIGO. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl KDIGO 2012;2 Suppl 2:143-274.
Trihono PP, Alatas H, Tambunan T, Pardede SO. Konsensus Tata Laksana Sindrom Nefrotik Idiopatik Pada Anak. Edisi kedua. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia; 2012. p. 1-20.
Andolino TP, Reid-Adam J. Nephrotic syndrome. Pediatr Rev 2015;36(3):117-25.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporos Int 2007;18(10):1319-28.
Tripathy A, Adiga S, Shah HH, Shanbhag TV, Kumar DM. Retrospective study of clinical profile and drug prescribing pattern in osteoporosis in a tertiary care hospital. Int J Pharm Pharm Sci 2015;7(10):390-3.
Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9(1):30.
Hansen KE, Kleker B, Safdar N, Bartels CM. A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthritis Rheum 2014;44(1):47-54.
Jagtap VR, Ganu JV. Serum osteocalcin: A specific marker for bone formation in postmenopausal osteoporosis. Int J Pharm Biol Sci 2011;1(4):510-7.
Ali SH, Kasim AA. Relationship between undercarboxylated osteocalcin and osteoprotegerin in knee osteoarthritis. Int J Pharm Pharm Sci 2014;6(11):344-6.
Ivaska K. Osteocalcin. Novel insights into the use of osteocalcin as a determinant of bone metabolism. Finland: Institute of Biomedicine, Department of Anatomy, University of Turku; 2005. p. 1-114.
Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem 2000;37:432-46.
Correia A, Azevedo Mdo S, Gondim F, Bandeira F. Ethnic aspects of vitamin D deficiency. Arq Bras Endocrinol Metabol 2014;58(5):540-4.
Neve A, Corrado A, Cantatore FP. Osteocalcin: Skeletal and extra-skeletal effects. J Cell Physiol 2013;228(6):1149-53.
Mitchell BD, Cole SA, Bauer RL, Iturria SJ, Rodriguez EA, Blangero J, et al. Genes influencing variation in serum osteocalcin concentrations are linked to markers on chromosomes 16q and 20q. J Clin Endocrinol Metab 2000;85(4):1362-6.
Davies JH, Evans BA, Gregory JW. Bone mass acquisition in healthy children. Arch Dis Child 2005;90(4):373-8.
McGuigan F, Kumar J, Ivaska KK, Obrant KJ, Gerdhem P, Akesson K. Osteocalcin gene polymorphisms influence concentration of seum osteocalcin and enhance fracture identification. J Bone Miner Res 2010;25(6):1392-9.
Heaney RP, Layman DK. Amount and type of protein influences bone health. Am J Clin Nutr 2008;87(5):1567S-70.
Kano K, Hoshi M, Nishikura K, Yamada Y, Arisaka O. Skeletal effects of short-term prednisolone therapy in children with steroid-responsive nephrotic syndrome. Clin Exp Nephrol 2001;5:40-3.
Mohamed GB, Abdel-Latif EA. Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome. Saudi J Kidney Dis Transpl 2011;22(5):955-62.
Godschalk MF, Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 1988;3(1):113-5.
Biyikli NK, Emre S, Sirin A, Bilge I. Biochemical bone markers in nephrotic children. Pediatr Nephrol 2004;19(8):869-73.
Freundlich M, Alonzo E, Bellorin-Font E, Weisinger JR. Increased osteoblastic activity and expression of receptor activator of NF-kappaB ligand in nonuremic nephrotic syndrome. J Am Soc Nephrol 2005;16(7):2198-204.
Lee WT, Jiang J. Calcium requirements for Asian children and adolescents. Asia Pac J Clin Nutr 2008;17 Suppl 1:33-6.
Pankova S, Tsvetkova D. Role of phytoestrogens in prevention of osteoporosis. Int J Curr Pharm Res 2015;7(2):1-6.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
